Mark Velleca Net Worth

The estimated Net Worth of Mark A. Velleca is at least $4.83 millió dollars as of 8 August 2023. Mr. Velleca owns over 60,000 units of G1 Therapeutics Inc stock worth over $846,431 and over the last 7 years he sold GTHX stock worth over $0. In addition, he makes $3,983,440 as President, Chief Executive Officer és Director at G1 Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Velleca GTHX stock SEC Form 4 insiders trading

Mark has made over 29 trades of the G1 Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of GTHX stock worth $23,400 on 8 August 2023.

The largest trade he's ever made was exercising 80,000 units of G1 Therapeutics Inc stock on 16 August 2022 worth over $31,200. On average, Mark trades about 13,327 units every 48 days since 2017. As of 8 August 2023 he still owns at least 118,714 units of G1 Therapeutics Inc stock.

You can see the complete history of Mr. Velleca stock trades at the bottom of the page.

Mark Velleca biography

Mark A. Velleca M.D. Ph.D. has been appointed as Director of the Company effective 1/1/2021. Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010, where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010, Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012, where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012, and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis. Velleca’s perspective and experience as our Chief Executive Officer and President, as well as his depth of experience in the biotechnology industry, provide him with the qualifications and skills to serve on our Board of Directors.

What is the salary of Mark Velleca?

As the President, Chief Executive Officer és Director of G1 Therapeutics Inc, the total compensation of Mark Velleca at G1 Therapeutics Inc is $3,983,440. There are 2 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.

How old is Mark Velleca?

Mark Velleca is 56, he's been the President, Chief Executive Officer és Director of G1 Therapeutics Inc since 2014. There are 13 older and 12 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.

What's Mark Velleca's mailing address?

Mark's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at G1 Therapeutics Inc

Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman és Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.

What does G1 Therapeutics Inc do?

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Complete history of Mr. Velleca stock trades at G1 Therapeutics Inc és Black Diamond Therapeutics Inc

G1 Therapeutics Inc executives and stock owners

G1 Therapeutics Inc executives and other stock owners filed with the SEC include:

• Mark Avagliano,
  Chief Business Officer
• James Hanson,
  General Counsel, Secretary
• Mark Velleca,
  President, Chief Executive Officer, Director
• Terry Murdock,
  Chief Operating Officer
• Garry Nicholson,
  Independent Chairman of the Board
• Jennifer Moses,
  Chief Financial Officer
• Rajesh Malik,
  Chief Medical Officer, Senior Vice President - Research and Development
• Dr. Mark A. Velleca M.D., Ph.D.,
  Sr. Advisor & Director
• Mark Avagliano,
  Chief Bus. Officer
• Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
  Chief Medical Officer and Sr. VP of R&D
• Dr. Rajesh K. Malik,
  Chief Medical Officer and Sr. VP of R&D
• Andrew Perry,
  Chief Commercial Officer
• Jennifer K. Moses CPA,
  Chief Financial Officer
• Jennifer K. Moses,
  Chief Financial Officer
• Seth Rudnick,
  Independent Director
• Glenn Muir,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Fredric Eshelman,
  Independent Director
• Willie Deese,
  Independent Director
• Andrew Witty,
  Independent Director
• John Bailey,
  Independent Director
• Soma Gupta,
  Chief Commercial Officer
• Jay Strum,
  Chief Scientific Officer
• Terry L. Murdock,
  Chief Operating Officer
• Blake Jensen,
  VP of Quality & Compliance
• William C. Roberts,
  VP of Investor Relations & Corp. Communications
• Dr. Jay C. Strum,
  Chief Scientific Officer
• Alexander D. Smith M.S.,
  VP of Technical Operations
• John E. Bailey Jr.,
  CEO, Pres & Director
• Clay Hatteras Venture Advis...,
  
• Capital Management, L.P.Ra ...,
  
• Christy L Shaffer,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Ventures, Llc Eshelman,
  10% owner
• Clay Hatteras Venture Advis...,
  
• Barclay A Phillips,
  SVP & Chief Financial Officer
• Monica R. Thomas,
  Chief Legal & People Officer
• Jacks Lee,
  
• John Demaree,
  Chief Commercial Officer
• Alicia Secor,
  
• Cynthia Louise Flowers,
  
• Andrew Perry,
  Chief Commercial Officer
• Norman Sharpless,
  
• John W. V Umstead,
  Chief Financial Officer